Phosphoantigen Prodrug Compounds
EPO Patent Bulletin - Pharma (A61K)
Summary
The European Patent Office granted patent EP3818064A1 for phosphoantigen prodrug compounds to University College Cardiff Consultants Ltd. and University of Birmingham. The patent covers novel chemical compounds with applications in immunology and oncology, classified under IPC C07F 9/44 and A61K 31/664. The patent is valid in 44 designated contracting states across Europe.
What changed
EPO published patent application EP3818064A1 for phosphoantigen prodrug compounds with inventors Mehellou and Willcox. The patent covers prodrug derivatives of phosphoantigens intended for immunological and anti-cancer applications.
For pharmaceutical companies and research institutions developing immunotherapy drugs, this patent establishes intellectual property rights in key European markets. The designated states include all major EU economies. Companies pursuing similar phosphoantigen-based therapeutics should evaluate freedom-to-operate implications in these territories.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHOSPHOANTIGEN PRODRUG COMPOUNDS
Publication EP3818064A1 Kind: A1 Apr 08, 2026
Applicants
University College Cardiff Consultants, Ltd., University of Birmingham
Inventors
MEHELLOU, Youcef, WILLCOX, Benjamin
IPC Classifications
C07F 9/44 20060101AFI20200110BHEP A61P 19/00 20060101ALI20200110BHEP A61K 31/664 20060101ALI20200110BHEP A61P 35/00 20060101ALI20200110BHEP A61P 37/00 20060101ALI20200110BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.